Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study
Status:
Completed
Trial end date:
2020-03-19
Target enrollment:
Participant gender:
Summary
This was an interventional, double-blind, placebo controlled, randomized, single dose,
proof-of-concept study. It was a single-center clinical trial.
The purpose of the study was to explore the clinical efficacy and safety of a single local IM
injection of gonyautoxin 2/3 (GTX 2/3) compared to placebo in decreasing pain and improving
lumbar functionality at short term follow-up in adult patients with acute low back pain,
without radiculopathy.